pimagedine

Small moleculeexperimental

Pimagedine, also known as aminoguanidine, is an investigational drug for the treatment of diabetic nephropathy that is no longer under development as a drug. Pimagedine functions as an inhibitor of diamine oxidase and nitric oxide synthase. It acts to reduce levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, glyoxal, methylglyoxal, and related dicarbonyls. These reactive species are converted to less reactive heterocycles by this condensation reaction. — Wikipedia

Clinical trial activity

4 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Sep 30, 2003 (NCT00159380)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

N=C(N)NN
Mol. weight
74.09 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • aminoguanidine
  • aminoguanidine
  • aminoguanidine
  • aminoguanidine
  • aminoguanidine sulfate
  • hydrazinecarboximidamide
  • hydrazinecarboximidamide
  • hydrazinecarboximidamide
  • monoaminoguanidine
  • pimagedine
  • pimagedine
  • pimagedine
  • pimagedine hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02099981Phase 1Jul 1, 2016University of Minnesota
NCT00184990Phase 1Jan 1, 2005Radboud University
NCT00180635N/AOct 31, 2003Imperial College London
NCT00159380N/ASep 30, 2003Imperial College London
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Imperial College LondonAcademic/Hospital2212003
Radboud UniversityAcademic/Hospital1112005
University of MinnesotaAcademic/Hospital1112016
3 organizations
Page 1 / 1